Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: Experimental results and first-in-man experience

Blood

Volumn 113, Issue 20, 2009, Pages 5019-5027

  Bieker, Ralf ^a   Kessler, Torsten ^a   Schwöppe, Christian ^a   Padró, Teresa ^a   Persigehl, Thorsten ^a   Bremer, Christoph ^a   Dreischalück, Johannes ^a   Kolkmeyer, Astrid ^a   Heindel, Walter ^a   Mesters, Rolf M ^a   Berdel, Wolfgang E ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HYBRID PROTEIN; MICROSOMAL AMINOPEPTIDASE; THROMBOPLASTIN; THROMBOPLASTIN NGR; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ANGIOGENESIS INHIBITOR; NGR PEPTIDE; OLIGOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BLOOD CLOTTING; CANCER INHIBITION; CONTROLLED STUDY; DRUG BINDING; EXPERIMENTAL STUDY; FIBROSARCOMA; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SOLID TUMOR; THROMBOGENICITY; THROMBOSIS; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ADULT; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG SCREENING; EMBOLISM; FEMALE; METABOLISM; METHODOLOGY; MIDDLE AGED; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; SALVAGE THERAPY; VASCULARIZATION;

ADULT; ANGIOGENESIS INHIBITORS; ANIMALS; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; EMBOLISM; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; SALVAGE THERAPY; THROMBOPLASTIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66549114936     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-04-150318     Document Type: Article

References (40)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat Med. 1995;1:27-31.
2. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389-395.
3. Bieker R, Padro T, Kramer J, et al. Overexpression of basic fibroblast growth factor and autocrine stimulation in acute myeloid leukemia. Cancer Res. 2003;63:7241-7246. (Pubitemid 37413463)
4. Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95:2637-2644. (Pubitemid 30210544)
5. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364. (Pubitemid 26272076)
6. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989;339:58-61. (Pubitemid 19115892)
7. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 1999;5:1359-1364.
8. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279:377-380. (Pubitemid 28063372)
9. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science. 1999;285:1926-1928. (Pubitemid 129515517)
10. Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res. 2001;61:711-716. (Pubitemid 32128637)
11. Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorpe PE. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res. 1998;58:4646-4653. (Pubitemid 28480630)
12. Huang X, Molema G, King S,Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science. 1997;275:547-550. (Pubitemid 27051913)
13. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood. 1993;81:734-744.
14. Liu C, Huang H, Donate F, et al. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res. 2002;62:5470-5475.
15. Kessler T, Bieker R, Padro T, et al. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. Clin Cancer Res. 2005;11:6317-6324. (Pubitemid 41262963)
16. Pasqualini R, Koivunen E, Kain R, et al. Amino-peptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 2000;60:722-727. (Pubitemid 30094573)
17. Pasqualini R, Koivunen E, Ruoslahti E. A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins. J Cell Biol. 1995;130:1189-1196.
18. Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R, Shapiro LH. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood. 2001;97:652-659. (Pubitemid 32113397)
19. Drexler HG. Classification of acute myeloid leukemias - a comparison of FAB and immunophenotyping. Leukemia. 1987;1:697-705.
20. Riemann D, Kehlen A, Langner J. CD13 - not just a marker in leukemia typing. Immunol Today. 1999;20:83-88. (Pubitemid 29136633)
21. Curnis F, Arrigoni G, Sacchi A, et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res. 2002;62:867-874. (Pubitemid 34126966)
22. Corti A, Curnis F, Arap W, Pasqualini R. The neovasculature homing motif NGR: more than meets the eye. Blood. 2008;112:2628-2635.
23. Ruf W, Rehemtulla A, Morrissey JH, Edgington TS. Phospholipid-independent and-dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem. 1991;266:2158-2166. (Pubitemid 21909043)
24. Topp MS, Koenigsmann M, Mire-Sluis A, et al. Recombinant human interleukin-4 inhibits growth of some human lung tumor cell lines in vitro and in vivo. Blood. 1993;82:2837-2844. (Pubitemid 23318092)
25. Topp MS, Papadimitriou CA, Eitelbach F, et al. Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies. Cancer Res. 1995;55:2173-2176.
26. Rasheed S, Nelson-Rees WA, Toth EM, Arnstein P, Gardner MB. Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer. 1974;33:1027-1033.
27. Vose JM. Immunotherapy for non-Hodgkin's lymphoma. Oncology (Williston Park). 2001;15:141-155.
28. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 1997;26:71-90. (Pubitemid 27289526)
29. Neumeister P, Eibl M, Zinke-Cerwenka W, Scarpatetti M, Sill H, Linkesch W. Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate. Ann Hematol. 2001;80:119-120. (Pubitemid 32177960)
30. Thomas GE, Esteban JM, Raubitschek A, Wong JY. γ-Interferon administration after 90yttrium radiolabeled antibody therapy: survival and hematopoietic toxicity studies. Int J Radiat Oncol Biol Phys. 1995;31:529-534.
31. Banner DW, D'Arcy A, Chene C, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature. 1996;380:41-46. (Pubitemid 26076234)
32. Aina OH, Sroka TC, Chen ML, Lam KS. Therapeutic cancer targeting peptides. Biopolymers. 2002;66:184-199.
33. Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (N Y). 1995;13:265-270.
34. Pasqualini R, Arap W. Profiling the molecular diversity of blood vessels. Cold Spring Harb Symp Quant Biol. 2002;67:223-225. (Pubitemid 36775515)
35. Bhagwat SV, Petrovic N, Okamoto Y, Shapiro LH. The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis. Blood. 2003;101:1818-1826. (Pubitemid 36237579)
36. Dixon J, Kaklamanis L, Turley H, et al. Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. J Clin Pathol. 1994;47:43-47. (Pubitemid 24057748)
37. Colombo G, Curnis F, De Mori GM, et al. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem. 2002;277:47891-47897. (Pubitemid 36159317)
38. Bevers EM, Rosing J, Zwaal RF. Development of procoagulant binding sites on the platelet surface. Adv Exp Med Biol. 1985;192:359-371.
39. Dachary-Prigent J, Toti F, Satta N, Pasquet JM, Uzan A, Freyssinet JM. Physiopathological significance of catalytic phospholipids in the generation of thrombin. Semin Thromb Hemost. 1996;22:157-164. (Pubitemid 26239909)
40. Ortel TL, Quinn-Allen MA, Charles LA, Devore-Carter D, Kane WH. Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity. J Clin Invest. 1992;90:2340-2347.